YM 638

Drug Profile

YM 638

Alternative Names: YM 16638

Latest Information Update: 09 Aug 2002

Price : $50

At a glance

  • Originator Yamanouchi
  • Class Antiasthmatics; Antiulcers; Cytoprotectives
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Asthma; Hyperlipidaemia; Peptic ulcer

Most Recent Events

  • 07 May 1999 A study has been added to the Hyperlipidaemia pharmacodynamics section
  • 07 May 1999 Phase-I clinical trials for Hyperlipidaemia in Japan (Unknown route)
  • 30 Jul 1998 No-Development-Reported for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top